Hims & Hers Health is revolutionizing telehealth with a vertically integrated model, offering personalized medications and achieving rapid subscription growth, driving long-term profitability and ...
Below is Validea's guru fundamental report for HIMS & HERS HEALTH INC (HIMS). Of the 22 guru strategies we follow, HIMS rates highest using our P/B Growth Investor model based on the published ...
Craig Hettenbach, an analyst from Morgan Stanley, maintained the Buy rating on Hims & Hers Health (HIMS – Research Report). The associated price target remains the same with $42.00. Discover the ...
Geode Capital Management LLC increased its position in shares of Hims & Hers Health, Inc. (NYSE:HIMS – Free Report) by 12.7% during the 3rd quarter, according to its most recent 13F filing with ...